Seven Eight Capital’s Avanos Medical AVNS Stock Holding History

Seven Eight Capital’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-21,700	Closed	-$1.49M	–	536
2018 Q3	$1.49M	Buy	+21,700	New	+$1.4M	0.09%	299
2015 Q3	–	Sell	-300	Closed	-$12K	–	527
2015 Q2	$12K	Buy	+300	New	+$13.5K	0.01%	446

Other funds holding AVNS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Seven Eight Capital's AVNS Position: Q4 2018 in Review

Seven Eight Capital sold out of Avanos Medical (AVNS) in Q4 2018, closing a stake of 21,700 shares — an estimated $1.49M sold.

Seven Eight Capital first reported a position in AVNS in Q2 2015 and held it in 2 quarters. The position peaked at $1.49M in Q3 2018. 350 funds tracked by Wall St. Rank hold AVNS as of Q4 2018.

Seven Eight Capital reported no remaining Avanos Medical position as of Q4 2018 after selling out during the quarter.
Seven Eight Capital sold 21,700 Avanos Medical shares in Q4 2018, an estimated $1.49M.
Seven Eight Capital first reported a position in Avanos Medical in Q2 2015 and held it in 2 quarters.
Seven Eight Capital's Avanos Medical position peaked at $1.49M in Q3 2018.
350 funds tracked by Wall St. Rank held Avanos Medical as of Q4 2018.

Based on Seven Eight Capital's 13F filing for Q4 2018, filed 14 Feb 2019.